Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FAMILY MEDICINE CLINIC OF FEDERAL WAY

NPI: 1629113956 · FEDERAL WAY, WA 98003 · Specialist · NPI assigned 02/21/2007

$641K
Total Medicaid Paid
16,191
Total Claims
12,766
Beneficiaries
23
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialLENG, VUTHY (OWNER)
NPI Enumeration Date02/21/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,743 $56K
2019 2,500 $136K
2020 2,959 $133K
2021 3,283 $122K
2022 2,091 $81K
2023 1,980 $61K
2024 1,635 $52K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 8,730 6,953 $317K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,269 1,018 $100K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,224 1,604 $94K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1,868 1,439 $74K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 153 117 $14K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 252 117 $13K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 110 86 $11K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 172 163 $8K
80305 530 454 $5K
84443 Thyroid stimulating hormone (TSH) 92 91 $1K
99422 60 56 $1K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 112 99 $630.85
36415 Collection of venous blood by venipuncture 250 237 $616.00
83036 Hemoglobin; glycosylated (A1C) 111 105 $604.52
99453 26 26 $524.11
90688 26 23 $342.16
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 45 41 $151.44
G0438 Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit 14 14 $151.42
90658 12 12 $96.72
82570 25 16 $23.36
83986 24 16 $13.00
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 16 15 $8.71
99072 70 64 $0.00